About Neophore

NeoPhore develops small molecule therapeutics that broaden cancer patient access to powerful immunotherapy. The company targets the DNA mismatch repair pathway to transform tumours that are normally unresponsive to immune checkpoint therapy into an immune-responsive state, mimicking the robust clinical responses observed in patients with genetically deficient DNA mismatch repair. By transiently blocking mismatch repair with pharmacological inhibitors, NeoPhore aims to reprogramme previously resistant tumours, expanding the population of cancer patients who can benefit from durable immunotherapy responses. The company operates from South London and collaborates with leading academic organisations worldwide.